NPM1 and Myelodysplasia: The newer guidelines also outline that NPM1-mutated AML with concurrent adverse-risk cytogenetic changes are linked to adverse risk, while research is ongoing regarding the implications of other abnormalities, such as myelodysplasia-related mutations, when paired with mutated NPM1 [4].